Phase IIb trial of a novel TB vaccine

This vaccine represents a paradigm shift in the fact that this is the first pre-exposure vaccine to target prevention of TB infection. The project was recently showcased by EU (EDCTP) on the World TB day. It is funded by RCN-GLOBVAC and the project is coordinated from K2 by Harleen Grewal. It is every reason to congratulate, Harleen!

Leave a Reply

Your email address will not be published. Required fields are marked *